



---

## OBTAINING OF PRACTICE LICENCE OF MEDICAL INSTITUTION BY BEIJING DEYI SHANSHUI CLINIC CO., LTD.

---

### 1. Introduction

The Board of Directors (the “**Board**”) of TalkMed Group Limited (the “**Company**” and together with its subsidiaries and associated company, collectively the “**Group**”) refers to the Company’s announcement dated 12 April 2021 on the obtaining of practice licence of medical institution by Sino-Singapore Cancer Centre (“**SSCC**”), a category 2A oncology hospital that is located in Yongchuan, Western Chongqing and part of the Group’s network of medical facilities.

### 2. Obtaining of practice licence of medical institution by Beijing Deyi Shanshui Clinic Co., Ltd. (“**BDSC**”)

2.1 The Board is pleased to announce that TalkMed Shanshui Medical Centre (北京德医山水诊所) (“**TSMC**”), an outpatient medical centre in Beijing, which was set up by the Group through BDSC in which the Company has 100% effective interest, has obtained the practice licence of medical institution, making Beijing the second city in the People’s Republic of China (“**PRC**”) that the Group will operate in, after SSCC in Chongqing.

2.2 Operating on a gross floor area of approximately 1,100 square metres, TSMC will provide access to private premier and quality oncology treatment as well as support services for oncology patients, with key services such as cancer diagnosis and precision treatment, cancer treatment with fast track access to Singapore’s healthcare system, and rehabilitation services, amongst others.

2.3 These services will be delivered by a multidisciplinary team comprising oncologists and other specialist professionals from both local and overseas and are leaders in their respective fields.

2.4 TSMC will also provide an oncology care platform for local medical oncologists across the PRC to practise quality patient care and eventually build strong medical oncology practices in the PRC.

### 3. Financial effects

The TSMC is not expected to have any material impact on the net tangible assets per share and earnings per share of the Group for the financial year ending 31 December 2021.



#### 4. Interests of Directors and Substantial or Controlling Shareholders

None of the Directors and, to the best knowledge of the Directors, none of the substantial shareholders or controlling shareholders of the Company, has any direct or indirect interest in the investment in BDSC.

By Order of the Board

Dr Ang Peng Tiam  
Chief Executive Officer  
3 May 2021

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, Hong Leong Finance Limited. This announcement has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr Kaeson Chui, Vice President, at 16 Raffles Quay, #01-05 Hong Leong Building, Singapore 048581, Telephone number: (65) 6415 9886*